Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2018.01519 http://scihub22266oqcxt.onion/10.3389/fimmu.2018.01519 C6036112!6036112 !30013569     free     free     free       Front+Immunol 2018 ; 9 (?): 1519 Nephropedia Template TP {{tp|p=30013569 |t=2018. CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: ?-Galactosylceramide and Beyond |pdf=|usr=}}{{30013569 }} gab.com Text CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: -Galactosylceramide and Beyond JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=30013569 #FOAvip CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an antitumor immune response via their rapid production of proinflammatory cytokines that trigger the cytotoxic machinery of other components of the innate and adaptive immune system. Here, we provide an overview of various therapeutic approaches that have been evaluated or that are currently being developed and/or explored. These include administration of ?-GalCer or alternative (glyco) lipid antigens, glycolipid-loaded antigen-presenting cells and liposomes, strategies that enhance CD1d expression levels or are based on ligation of CD1d, adoptive transfer of iNKT cells or chimeric antigen receptor iNKT cells, and tumor targeting of iNKT cells. Twit Text FOAVip CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: -Galactosylceramide and Beyond ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=30013569 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30013569 #FOAvip English Wikipedia <ref>{{Cite pmid|30013569 }}</ref> CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: ?-Galactosylceramide and Beyond #MMPMID30013569 King LA ; Lameris R ; de Gruijl TD ; van der Vliet HJ Front Immunol 2018[]; 9 (?): 1519 PMID30013569 show ga CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an antitumor immune response via their rapid production of proinflammatory cytokines that trigger the cytotoxic machinery of other components of the innate and adaptive immune system. Here, we provide an overview of various therapeutic approaches that have been evaluated or that are currently being developed and/or explored. These include administration of ?-GalCer or alternative (glyco) lipid antigens, glycolipid-loaded antigen-presenting cells and liposomes, strategies that enhance CD1d expression levels or are based on ligation of CD1d, adoptive transfer of iNKT cells or chimeric antigen receptor iNKT cells, and tumor targeting of iNKT cells. ?CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: ?-G(epmc).pdf DeepDyve Pubget Overpricing